Analyst Reco. Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:51:12 15/01/2026 GMT			5-day change	1st Jan Change
22.41 ^USD	-3.74%		-2.28%	+3.52%

01-14	Legend Biotech Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09:00 AM
01-12	Legend Biotech highlights recent business updates at 44th annual J.P. Morgan Healthcare conference	RE

Analyst Reco.

01-08	RBC Cuts Price Target on Legend Biotech to $66 From $74, Keeps Outperform Rating	MT
01-07	Oppenheimer Initiates Legend Biotech at Outperform With $75 Price Target	MT
12-10	Legend Biotech's Stock Weakness After Rival Treatment Update 'Overdone,' RBC Says	MT
12-08	UBS Adjusts Legend Biotech Price Target to $48 From $54, Maintains Buy Rating	MT
11-13	RBC Trims Price Target on Legend Biotech to $74 From $75, Keeps Outperform Rating	MT
11-13	Truist Lowers Price Target on Legend Biotech to $70 From $71, Keeps Buy Rating	MT
08/10/25	RBC Trims Price Target on Legend Biotech to $75 From $77, Keeps Outperform Rating	MT
12/08/25	RBC Capital Adjusts Price Target on Legend Biotech to $77 From $75, Maintains Outperform Rating	MT
07/07/25	RBC Lowers Price Target on Legend Biotech to $75 From $78, Keeps Outperform Rating	MT
03/07/25	UBS Lowers Price Target on Legend Biotech to $54 From $60, Maintains Buy Rating	MT
14/05/25	Truist Securities Adjusts Legend Biotech Price Target to $71 From $88, Maintains Buy Rating	MT
07/01/25	RBC Trims Price Target on Legend Biotech to $84 From $86, Keeps Outperform Rating	MT
09/12/24	UBS Lowers Legend Biotech Price Target to $65 From $75, Maintains Buy Rating	MT
08/10/24	Redburn Initiates Legend Biotech at Buy With $86 Price Target	MT
15/07/24	TD Cowen Adjusts Legend Biotech Price Target to $67 From $71, Maintains Buy Rating	MT
17/06/24	Truist Securities Initiates Legend Biotech With Buy Rating, $88 Price Target	MT
24/05/24	HC Wainwright Adjusts Legend Biotech Price Target to $73 From $86, Maintains Buy Rating	MT
24/05/24	Deutsche Bank Starts Legend Biotech With Buy Rating	MT
14/05/24	HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating	MT
14/05/24	RBC Adjusts Price Target on Legend Biotech to $86 From $85 on Model Updates, Maintains Outperform Rating	MT
17/04/24	Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65	MT
03/04/24	Cantor Fitzgerald Initiates Legend Biotech With Overweight Rating	MT
18/03/24	UBS Adjusts Legend Biotech Price Target to $81 From $76, Maintains Buy Rating	MT
13/03/24	Raymond James Starts Legend Biotech With Outperform Rating, $86 Price Target	MT
03/01/24	RBC Trims Price Target on Legend Biotech to $85 From $86, Keeps Outperform Rating	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Analyst Reco. Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Analyst Reco.

Filters